57461-53-7

Basic information

• Product Name: methyl 2-[(3-nitropyridin-2-yl)amino]acetate
• Synonyms: methyl 2-[(3-nitropyridin-2-yl)amino]acetate
• CAS NO: 57461-53-7
• Molecular Formula: C8H9N3O4
• Molecular Weight: 211.17476
• Mol File: 57461-53-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 346.769°C at 760 mmHg
• Flash Point: 163.52°C
• Appearance: /
• Density: 1.404g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.601
• CAS DataBase Reference: methyl 2-[(3-nitropyridin-2-yl)amino]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-[(3-nitropyridin-2-yl)amino]acetate(57461-53-7)
• EPA Substance Registry System: methyl 2-[(3-nitropyridin-2-yl)amino]acetate(57461-53-7)

Safety Data

• Hazardous Substances Data: 57461-53-7(Hazardous Substances Data)

Usage

General Description

Methyl 2-[(3-nitropyridin-2-yl)amino]acetate is a chemical compound with the molecular formula C8H9N3O4. It is a yellow solid with a molecular weight of 199.17 g/mol. methyl 2-[(3-nitropyridin-2-yl)amino]acetate is often used as an intermediate in the synthesis of pharmaceuticals and agrochemicals, and has potential applications in organic chemistry. It is important to handle this compound with care, as it is classified as a hazardous substance and may cause skin and eye irritation upon contact. Additionally, it should be stored in a cool, dry place away from direct sunlight and sources of ignition.

InChI:InChI=1/C8H9N3O4/c1-15-7(12)5-10-8-6(11(13)14)3-2-4-9-8/h2-4H,5H2,1H3,(H,9,10)

Upstream product

• 67-56-1 methanol 
• 4214-75-9 2-amino-3-nitropyridine 
• 131543-46-9 Glyoxal 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 5680-79-5 glycine ethyl ester hydrochloride 

Downstream Products

• 67074-78-6 3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one 

Relevant articles and documents

Heteroaromatic Inhibitors of the Astacin Proteinases Meprin α, Meprin β and Ovastacin Discovered by a Scaffold-Hopping Approach

Astacin metalloproteinases, in particular meprins α and β, as well as ovastacin, are emerging drug targets. Drug-discovery efforts have led to the development of the first potent and selective inhibitors in the last few years. However, the most recent compounds are based on a highly flexible tertiary amine scaffold that could cause metabolic liabilities or decreased potency due to the entropic penalty upon binding to the target. Thus, the aim of this study was to discover novel conformationally constrained scaffolds as starting points for further inhibitor optimization. Shifting from flexible tertiary amines to rigid heteroaromatic cores resulted in a boost in inhibitory activity. Moreover, some compounds already exhibited higher activity against individual astacin proteinases compared to recently reported inhibitors and also a favorable off-target selectivity profile, thus qualifying them as very suitable chemical probes for target validation.

Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders

Phosphodiesterase (PDE) 2A inhibitors have emerged as a novel mechanism with potential therapeutic option to ameliorate cognitive dysfunction in schizophrenia or Alzheimer's disease through upregulation of cyclic nucleotides in the brain and thereby achieve potentiation of cyclic nucleotide signaling pathways. This article details the expedited optimization of our recently disclosed pyrazolo[1,5-a]pyrimidine lead compound 4b, leading to the discovery of clinical candidate 36 (TAK-915), which demonstrates an appropriate combination of potency, PDE selectivity, and favorable pharmacokinetic (PK) properties, including brain penetration. Successful identification of 36 was realized through application of structure-based drug design (SBDD) to further improve potency and PDE selectivity, coupled with prospective design focused on physicochemical properties to deliver brain penetration. Oral administration of 36 demonstrated significant elevation of 3′,5′-cyclic guanosine monophosphate (cGMP) levels in mouse brains and improved cognitive performance in a novel object recognition task in rats. Consequently, compound 36 was advanced into human clinical trials.

HETEROCYCLIC COMPOUND

The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the f